Skip to main content
Figure 1 | BMC Cancer

Figure 1

From: Sunitinib in combination with trastuzumab for the treatment of advanced breast cancer: activity and safety results from a phase II study

Figure 1

Antitumor activity of sunitinib plus trastuzumab. (A) Maximum reduction in target lesion size by patient, with confirmed responses based on RECIST indicated. Broken gray lines indicate cut-offs for progressive disease and partial responses. (B) and (C) Kaplan–Meier estimates of (B) progression-free survival and (C) overall survival. RECIST, Response Evaluation Criteria in Solid Tumors.

Back to article page